Department of Internal Medicine, Inje University College of Medicine, Haeundae Paik Hospital, Busan, South Korea.
Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
J Gastroenterol Hepatol. 2021 Aug;36(8):2315-2323. doi: 10.1111/jgh.15462. Epub 2021 Mar 7.
While recent evidences support endoscopic resection as curative in ampullary tumors with high-grade intraepithelial neoplasia, only small case series have reported endoscopic management of early-stage ampullary cancer; thus, radical surgery remains the only accepted treatment modality. We evaluated the long-term outcomes of early ampullary adenocarcinoma administered endoscopic management.
We retrospectively reviewed electronic medical records of 715 patients undergoing endoscopic papillectomy (EP) in a single tertiary medical center in Korea in 2004-2016. We included patients incidentally diagnosed with early-stage adenocarcinoma (Tis and T1a, American Joint Committee on Cancer 8th edition) after EP and with >2 years of follow-up data and analyzed their demographics, histopathologic data, and clinical outcomes.
Among 70 total patients in the EP-alone (n = 42) and subsequent surgery (n = 28) groups, we observed no significant differences in demographics or tumor size (2.0 ± 0.6 vs 1.9 ± 0.5 cm, P = 0.532), histologic grade (P = 0.077), tumor extent (P = 1.000), lymphovascular invasion (2.4% vs 10.7%, P = 0.344), or complete resection rates (57.1% vs 57.1%, P = 1.000) between groups. Adenocarcinoma lesions were larger in the subsequent surgery group (0.7 ± 0.5 vs 1.1 ± 0.7 cm, P = 0.002). The EP-alone group received more additional ablative treatment (42.9% vs 14.3%, P = 0.024). The 5-year disease-free and cancer-free survival rates were 79.1% vs 87.4% (P = 0.111) and 93.5% versus 87.4% (P = 0.726), respectively, and did not differ significantly between groups.
Endoscopic papillectomy followed by endoscopic surveillance showed long-term outcomes comparable with surgical resection for early ampullary cancer and maybe curable alternative to surgery for incidentally found early-stage ampullary cancer, especially in patients unfit for or refusing radical surgery.
尽管最近的证据支持对高级别上皮内瘤变的壶腹肿瘤进行内镜下切除作为治愈方法,但只有小的病例系列报告了早期壶腹癌的内镜治疗;因此,根治性手术仍然是唯一被接受的治疗方式。我们评估了接受内镜治疗的早期壶腹腺癌患者的长期结果。
我们回顾性分析了 2004 年至 2016 年在韩国一家三级医疗中心接受内镜乳头切开术(EP)的 715 例患者的电子病历。我们纳入了在 EP 后偶然诊断为早期腺癌(Tis 和 T1a,美国癌症联合委员会第 8 版)且随访时间超过 2 年的患者,并分析了他们的人口统计学、组织病理学数据和临床结果。
在 EP 单独治疗(n=42)和随后手术治疗(n=28)的 70 例患者中,我们观察到两组在人口统计学或肿瘤大小(2.0±0.6 与 1.9±0.5 cm,P=0.532)、组织学分级(P=0.077)、肿瘤范围(P=1.000)、淋巴血管侵犯(2.4%与 10.7%,P=0.344)或完全切除率(57.1%与 57.1%,P=1.000)方面均无显著差异。随后手术组的腺癌病变较大(0.7±0.5 与 1.1±0.7 cm,P=0.002)。EP 单独治疗组接受了更多的附加消融治疗(42.9%与 14.3%,P=0.024)。5 年无病生存率和无癌生存率分别为 79.1%和 87.4%(P=0.111)和 93.5%和 87.4%(P=0.726),两组之间无显著差异。
内镜乳头切开术加内镜随访显示出与手术切除早期壶腹癌相当的长期结果,对于偶然发现的早期壶腹腺癌,可能是手术的可替代治疗方法,尤其是对于不适合或拒绝根治性手术的患者。